Individualised neoantigen therapy mRNA-4157 (V940) plus pembrolizumab versus pembrolizumab monotherapy in resected melanoma (KEYNOTE-942): a randomised, phase 2b studyJeffrey S. Weber, Tal Zaks, George Ansstas et al.|The Lancet|2024Cited by 729
Evaluation of Seropositivity Following BNT162b2 Messenger RNA Vaccination for SARS-CoV-2 in Patients Undergoing Treatment for CancerAmir Massarweh, Salomon M. Stemmer, Noa Eliakim‐Raz et al.|JAMA Oncology|2021Cited by 291